INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ:INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XPro^TM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.  The webcast will feature RJ Tesi, MD, CEO, CJ Barnum, PhD, head of Neuroscience, and Malu Tansey, PhD, Professor of Neuroscience and Neurology, Norman and Susan Fixel Chair in Parkinson’s Disease, Director, Parkinson’s Foundation Research Center of Excellence, University of Florida.

Read more at globenewswire.com